Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SKN022
MIFTS: 56

Skin Squamous Cell Carcinoma

Categories: Cancer diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Skin Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Skin 12 71
Squamous Cell Carcinoma of the Skin 6
Epidermoid Skin Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3151
NCIt 49 C4819
UMLS 71 C0553723
Sources

Summaries for Skin Squamous Cell Carcinoma

About this section
Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to exanthem and squamous cell papilloma. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Fluorouracil and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and colon, and related phenotypes are cellular and growth/size/body region

Sources

Related Diseases for Skin Squamous Cell Carcinoma

About this section

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
# Related Disease Score Top Affiliating Genes
1 exanthem 31.1 MAP2K7 IL10 HRAS
2 squamous cell papilloma 30.9 TP53 HRAS
3 thyroid carcinoma 30.6 TP53 HRAS BRAF
4 leukemia, acute myeloid 30.5 TP53 STAT1 MIR154 MAP2K7 KLF4 IL10
5 leukemia, chronic lymphocytic 30.4 TP53 STAT1 MIR154 MAP2K7 IL10 IFNA1
6 leukemia, chronic myeloid 30.3 TP53 STAT1 RAF1 MAP2K7 IFNA1 HRAS
7 glioblastoma multiforme 30.3 TP53 STAT1 RAF1 RAC1 HRAS BRAF
8 renal cell carcinoma, nonpapillary 30.2 TP53 STAT1 RAF1 IFNA1 HRAS BRAF
9 lentigines 30.1 RAF1 BRAF
10 lung cancer susceptibility 3 30.0 TP53 STAT1 RAF1 RAC1 MIR154 MAP2K7
11 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.8
12 pseudovascular skin squamous cell carcinoma 12.4
13 acantholytic squamous cell skin carcinoma 11.9
14 epidermodysplasia verruciformis 1 11.6
15 clear cell squamous cell skin carcinoma 11.6
16 anal margin squamous cell carcinoma 11.4
17 squamous cell carcinoma 10.9
18 nevus of ota 10.6 TP53 BRAF
19 herpangina 10.6 TP53 IL10 IFNA1
20 spitzoid melanoma 10.6 HRAS BRAF
21 vulvar disease 10.6 TP53 IFNA1 HRAS
22 hyperplastic polyposis syndrome 10.6 TP53 BRAF
23 breast squamous cell carcinoma 10.6 TP53 HRAS
24 dengue hemorrhagic fever 10.6 STAT1 IL10 IFNA1
25 severe acute respiratory syndrome 10.6 STAT1 IL10 IFNA1
26 maxillary sinus adenocarcinoma 10.6 TP53 STAT1
27 spitz nevus 10.6 TP53 HRAS BRAF
28 monoclonal gammopathy of uncertain significance 10.6 TP53 NSD2 HRAS
29 skin papilloma 10.5 TP53 MAP2K7 HRAS
30 plexiform neurofibroma 10.5 TP53 MAP2K7 HRAS
31 mouth disease 10.5 TP53 STAT1 IL10 IFNA1
32 mumps 10.5 STAT1 IL10 IFNA1
33 respiratory system benign neoplasm 10.5 TP53 RAF1 HRAS
34 noonan syndrome and noonan-related syndrome 10.5 RAF1 BRAF
35 thyroid tumor 10.5 TP53 HRAS BRAF
36 adult teratoma 10.5 TP53 HRAS
37 acquired immunodeficiency syndrome 10.5 TP53 IL10 IFNA1 HRAS
38 lung adenoma 10.5 TP53 RAF1 HRAS
39 colonic benign neoplasm 10.5 TP53 HRAS BRAF
40 differentiated thyroid carcinoma 10.5 TP53 HRAS BRAF
41 thyroiditis 10.5 IL10 IFNA1 BRAF
42 peptic ulcer disease 10.5 TP53 IL10 HRAS
43 acneiform dermatitis 10.5 MAP2K7 HRAS
44 skin carcinoma 10.5
45 chlamydia 10.5 RAF1 RAC1 IL10
46 serous cystadenocarcinoma 10.5 TP53 HRAS BRAF
47 cystadenocarcinoma 10.5 TP53 HRAS BRAF
48 wolffian duct adenocarcinoma 10.5 TP53 HRAS
49 rasopathy 10.5 RAF1 HRAS BRAF
50 thyroid gland disease 10.4 TP53 MIR154 MAP2K7 HRAS

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 BRAF CD151 IGF2BP1 IL10 KLF4 MAP2K7
2 growth/size/body region MP:0005378 10.29 BRAF CD151 HHATL HRAS IGF2BP1 IL10
3 endocrine/exocrine gland MP:0005379 10.27 BRAF HRAS IGF2BP1 IL10 KLF4 MAP2K7
4 cardiovascular system MP:0005385 10.25 BRAF CD151 HRAS IL10 KLF4 NSD2
5 homeostasis/metabolism MP:0005376 10.25 BRAF CD151 HRAS IGF2BP1 IL10 KLF4
6 hematopoietic system MP:0005397 10.2 BRAF CD151 IGF2BP1 IL10 KLF4 RAC1
7 craniofacial MP:0005382 10.18 BRAF HRAS IGF2BP1 IL10 KLF4 NSD2
8 digestive/alimentary MP:0005381 10.16 BRAF HRAS IGF2BP1 IL10 KLF4 NSD2
9 immune system MP:0005387 10.14 BRAF CD151 IGF2BP1 IL10 KLF4 RAC1
10 mortality/aging MP:0010768 10.13 BRAF CD151 HRAS IGF2BP1 IL10 KLF4
11 integument MP:0010771 10.11 BRAF CD151 HRAS IL10 KLF4 MAP2K7
12 muscle MP:0005369 9.86 BRAF IGF2BP1 IL10 RAC1 RAF1 RARRES2
13 neoplasm MP:0002006 9.85 BRAF CD151 HRAS IGF2BP1 IL10 KLF4
14 normal MP:0002873 9.61 BRAF FAT2 HRAS IL10 KLF4 MAP2K7
15 skeleton MP:0005390 9.28 BRAF HHATL HRAS IGF2BP1 IL10 NSD2
Sources

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

About this section

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4 51-21-8 3385
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3 Immunologic Factors Phase 4
4 Antimetabolites Phase 4
5 Immunosuppressive Agents Phase 4
6 Triamcinolone diacetate Phase 4
7 triamcinolone acetonide Phase 4
8 Triamcinolone hexacetonide Phase 4
9 Tin Fluorides Phase 4
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Mycophenolic acid Approved Phase 3 24280-93-1 446541
12
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
13
Lactitol Investigational Phase 3 585-88-6, 585-86-4 493591
14 Anti-Infective Agents Phase 3
15 Antirheumatic Agents Phase 3
16 Antifungal Agents Phase 3
17 Cyclosporins Phase 3
18 Calcineurin Inhibitors Phase 3
19
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
20
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
21
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
22
Gemcitabine Approved Phase 2 95058-81-4 60750
23
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
24
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
25
nivolumab Approved Phase 2 946414-94-4
26
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
27
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
28
Pembrolizumab Approved Phase 2 1374853-91-4
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
30
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
31
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
32
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
33
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
34
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
35
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
36
Lenalidomide Approved Phase 2 191732-72-6 216326
37
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
38
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
39
Levulinic acid Experimental Phase 2 123-76-2 11579
40 Antiviral Agents Phase 2
41 Sunscreening Agents Phase 1, Phase 2
42 Semaxinib Phase 2
43 Albumin-Bound Paclitaxel Phase 2
44 Cola Phase 2
45 Antimitotic Agents Phase 2
46 Antibodies, Monoclonal Phase 2
47 Immunoglobulins Phase 2
48 Antibodies Phase 2
49 Interferon alpha-2 Phase 2
50 interferons Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
2 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
3 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
4 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
5 A Multicentric, Randomized, Opened Study to Evaluate Efficacy on Renal Function of an Immunosuppressant Regimen Based on Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil, From the Second Year of Renal Transplantation Completed NCT00213590 Phase 3 cyclosporine A
6 Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance Terminated NCT02655068 Phase 3
7 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
8 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
9 Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT01198028 Phase 2 Erlotinib
10 A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses Completed NCT00002975 Phase 2 aminolevulinic acid
11 Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
12 Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms Completed NCT00021294 Phase 2 eflornithine;triamcinolone
13 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
14 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib
15 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
16 Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR. Completed NCT00240682 Phase 2 cetuximab
17 A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
18 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
19 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
20 Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) Completed NCT00625573 Phase 2 Abraxane
21 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
22 Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion Completed NCT03127670 Phase 2 Solanum melongena peel extract 0.05%
23 Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC) Completed NCT00464295 Phase 2 Capecitabine in HCC
24 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed NCT00212043 Phase 2 carboplatin and gemcitabine
25 Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC) Recruiting NCT03944941 Phase 2 Avelumab;Cetuximab
26 Phase II Study of Nivolumab in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin Recruiting NCT04204837 Phase 2 Nivolumab
27 UNresectable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy. A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab With Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma Recruiting NCT03737721 Phase 2
28 A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02218164 Phase 2 Pegylated Interferon alpha-2b;Capecitabine;5-FU
29 Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin Active, not recruiting NCT02883556 Phase 2 Pembrolizumab
30 A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma Active, not recruiting NCT02964559 Phase 2
31 CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG) Active, not recruiting NCT02056756 Phase 1, Phase 2 Carfilzomib
32 Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients Enrolling by invitation NCT02347813 Phase 2 Pioglitazone
33 A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Terminated NCT01823679 Phase 2 Capecitabine
34 Phase I-II Study of ZD1839 (IRESSA®), Cisplatin, and External-Beam Radiation Therapy in Patients With Locally Advanced, Non-Metastatic, Squamous Cell Carcinoma of the Head and Neck Terminated NCT00195078 Phase 1, Phase 2 ZD1839 (IRESSA);Cisplatin
35 A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology Terminated NCT00005097 Phase 2 Polyphenon E and Placebo
36 A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes Terminated NCT01379274 Phase 2 Lenalidomide and azacitidine combination
37 Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin Terminated NCT01059305 Phase 2 Erlotinib
38 A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old With Fitzpatrick Type I, II, III And IV Skin To UV-Radiation From Artificial Light Sources Withdrawn NCT00025051 Phase 2 celecoxib
39 Development of an Electrical Diagnostic for Melanoma and Other Cutaneous Malignancies Unknown status NCT00391300 Phase 1
40 A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions Completed NCT02428036 Phase 1
41 Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions Completed NCT01017185 Phase 1 HF10
42 Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions Completed NCT00103246 Phase 1 silicon phthalocyanine 4
43 Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma Recruiting NCT03291002 Phase 1
44 A Phase 1 Study of Talimogene Laherparepvec and Panitumumab in Patients With Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS) Not yet recruiting NCT04163952 Phase 1
45 Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
46 Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers Completed NCT00003611 acitretin
47 Use Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma Syndrome Completed NCT00025012 isotretinoin
48 Chemoprevention Trial of Acitretin Versus Placebo in Patients at High Risk for Basal Cell Carcinoma or Squamous Cell Carcinoma Completed NCT00644384 acitretin
49 Transcriptional Profiling of the Epidermal Response to Solar-Simulated Ultraviolet Radiation Completed NCT00099112
50 A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma Completed NCT03353077

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Sources

Genetic Tests for Skin Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Skin Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

40
Skin, Lymph Node, Colon, Salivary Gland, Kidney, Lung, Breast
Sources

Publications for Skin Squamous Cell Carcinoma

About this section

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 287)
# Title Authors PMID Year
1
Cancer Risk in Klippel-Trenaunay Syndrome. 61
31045469 2019
2
Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer. 61
31521610 2019
3
Relationship Between Level of Serum 25-Hydroxyvitamin D and Risk of Squamous Cell Carcinoma in an Iranian Population. 61
31723461 2019
4
Loss of Rab25 promotes the development of skin squamous cell carcinoma through the dysregulation of integrin trafficking. 61
31144312 2019
5
Transdermal delivery of small interfering RNAs with topically applied mesoporous silica nanoparticles for facile skin cancer treatment. 61
31506653 2019
6
CSL controls telomere maintenance and genome stability in human dermal fibroblasts. 61
31467287 2019
7
A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases. 61
31004003 2019
8
Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma. 61
31177167 2019
9
Squamous cell carcinoma of skin due to prolonged indwelling percutaneous nephrostomy catheter. 61
31129641 2019
10
Investigation on the Cancer Invasion and Metastasis of Skin Squamous Cell Carcinoma by Raman Spectroscopy. 61
31151168 2019
11
Silencing of EPHB2 promotes the epithelial-mesenchymal transition of skin squamous cell carcinoma-derived A431 cells. 61
30881495 2019
12
Effect of Doxorubicin on Squamous Cell Carcinoma of Skin: Assessment by MRI Relaxometry at 4.7T. 61
31412717 2019
13
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. 61
31112973 2019
14
Tamoxifen inhibits the proliferation of non‑melanoma skin cancer cells by increasing intracellular calcium concentration. 61
30226592 2018
15
Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression. 61
30559930 2018
16
Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma. 61
30383661 2018
17
Associations Between IL-10 Polymorphisms and Susceptibility to Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma: A Meta-Analysis. 61
30427744 2018
18
Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers. 61
29933892 2018
19
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. 61
29663367 2018
20
Inhibitory effect of microRNA-154 targeting WHSC1 on cell proliferation of human skin squamous cell carcinoma through mediating the P53 signaling pathway. 61
29727714 2018
21
Superficial resection combined with photodynamic therapy for successful treatment of facial lupus vulgaris with squamous cell carcinoma. 61
29476827 2018
22
IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. 61
29753746 2018
23
Novel RSPO1 mutation causing 46,XX testicular disorder of sex development with palmoplantar keratoderma: A review of literature and expansion of clinical phenotype. 61
29575617 2018
24
Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. 61
29428730 2018
25
Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. 61
30025490 2018
26
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. 61
29050985 2018
27
Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. 61
29843147 2018
28
125I seeds implantation for an elderly patient of skin squamous cell carcinomas with ulcer guided by ultrasound. 61
30589056 2018
29
CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development. 61
28904130 2017
30
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. 61
28945253 2017
31
Squamous Cell Carcinoma of Skin after 20 Years of Renal Transplantation. 61
29217883 2017
32
Leiomyosarcoma of the infratemporal fossa with perineurial spread along the right mandibular nerve: a case report. 61
28990793 2017
33
Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth. 61
28807942 2017
34
Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients. 61
28207636 2017
35
Characterisation of the cancer-associated glucocorticoid system: key role of 11β-hydroxysteroid dehydrogenase type 2. 61
28797028 2017
36
Automatic discrimination of actinic keratoses from clinical photographs. 61
28692931 2017
37
Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo. 61
28623128 2017
38
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. 61
28672959 2017
39
Effects of demethoxycurcumin on the viability and apoptosis of skin cancer cells. 61
28586041 2017
40
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. 61
27714753 2017
41
TCF7L1 promotes skin tumorigenesis independently of β-catenin through induction of LCN2. 61
28467300 2017
42
Quantitative phosphoproteomic analysis reveals system-wide signaling pathways regulated by site-specific phosphorylation of Keratin-8 in skin squamous cell carcinoma derived cell line. 61
28176443 2017
43
[Pathologic changes of spontaneous tumors in Sprague-Dawley and Wistar rats]. 61
28376591 2017
44
Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. 61
28593886 2017
45
Cancer cell of origin controls epithelial-to-mesenchymal transition in skin squamous cell carcinoma. 61
28607908 2017
46
An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin. 61
27601059 2017
47
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. 61
28507641 2017
48
Inguinal lymph node presenting as the delayed site of metastasis in early stage endometrial carcinoma: Case report. 61
28213066 2017
49
Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts. 61
28267785 2017
50
Association Between β-Genus Human Papillomavirus and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals-A Meta-analysis. 61
26720285 2016
Sources

Variations for Skin Squamous Cell Carcinoma

About this section

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

6 (show top 50) (show all 107) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
3 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
4 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
5 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
6 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
7 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
8 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
9 BRAF NM_004333.6(BRAF):c.1406G>A (p.Gly469Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
10 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
11 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
12 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
13 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
14 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
15 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
16 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
17 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
18 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
19 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
20 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
21 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val)SNV Pathogenic/Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
22 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
23 TP53 NM_000546.5(TP53):c.535C>T (p.His179Tyr)SNV Pathogenic/Likely pathogenic 127815 rs587780070 17:7578395-7578395 17:7675077-7675077
24 TP53 NM_000546.5(TP53):c.844C>T (p.Arg282Trp)SNV Pathogenic/Likely pathogenic 12364 rs28934574 17:7577094-7577094 17:7673776-7673776
25 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic/Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
26 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)SNV Pathogenic/Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
27 TP53 NM_000546.5(TP53):c.809T>C (p.Phe270Ser)SNV Pathogenic/Likely pathogenic 376594 rs1057519986 17:7577129-7577129 17:7673811-7673811
28 TP53 NM_000546.5(TP53):c.845G>C (p.Arg282Pro)SNV Pathogenic/Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
29 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr)SNV Likely pathogenic 376663 rs28934573 17:7577559-7577559 17:7674241-7674241
30 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro)SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242
31 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala)SNV Likely pathogenic 376665 rs1057520002 17:7577560-7577560 17:7674242-7674242
32 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro)SNV Likely pathogenic 376666 rs1057520003 17:7579314-7579314 17:7675996-7675996
33 TP53 NM_000546.5(TP53):c.646G>T (p.Val216Leu)SNV Likely pathogenic 376670 rs730882025 17:7578203-7578203 17:7674885-7674885
34 TP53 NM_000546.5(TP53):c.647T>G (p.Val216Gly)SNV Likely pathogenic 376671 rs1057520004 17:7578202-7578202 17:7674884-7674884
35 TP53 NM_000546.5(TP53):c.647T>A (p.Val216Glu)SNV Likely pathogenic 376672 rs1057520004 17:7578202-7578202 17:7674884-7674884
36 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu)SNV Likely pathogenic 376673 rs876660333 17:7577123-7577123 17:7673805-7673805
37 TP53 NM_000546.5(TP53):c.707A>G (p.Tyr236Cys)SNV Likely pathogenic 376693 rs730882026 17:7577574-7577574 17:7674256-7674256
38 TP53 NM_000546.5(TP53):c.810T>G (p.Phe270Leu)SNV Likely pathogenic 376595 rs1057519987 17:7577128-7577128 17:7673810-7673810
39 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp)SNV Likely pathogenic 376610 rs587780070 17:7578395-7578395 17:7675077-7675077
40 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro)SNV Likely pathogenic 376611 rs1057519991 17:7578394-7578394 17:7675076-7675076
41 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu)SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
42 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly)SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
43 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly)SNV Likely pathogenic 376652 rs121912651 17:7577539-7577539 17:7674221-7674221
44 TP53 NM_000546.5(TP53):c.814G>T (p.Val272Leu)SNV Likely pathogenic 12358 rs121912657 17:7577124-7577124 17:7673806-7673806
45 TP53 NM_000546.5(TP53):c.722C>T (p.Ser241Phe)SNV Likely pathogenic 12359 rs28934573 17:7577559-7577559 17:7674241-7674241
46 STK19 NM_004197.1(STK19):c.265G>A (p.Asp89Asn)SNV Likely pathogenic 76320 rs267600971 6:31940123-31940123 6:31972346-31972346
47 TP53 NM_000546.5(TP53):c.587G>C (p.Arg196Pro)SNV Likely pathogenic 231165 rs483352697 17:7578262-7578262 17:7674944-7674944
48 TP53 NM_000546.5(TP53):c.722C>G (p.Ser241Cys)SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
49 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Likely pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
50 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro)SNV Likely pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 15557)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM131595377 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.947C>T p.S316L 16:31062050-31062050 18
2 COSM131595368 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1886C>T p.P629L 16:31061111-31061111 18
3 COSM131595526 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.316C>T p.P106S 16:31064213-31064213 18
4 COSM143109510 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13:20002948-20002948 18
5 COSM129142467 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.672C>T p.F224= 3:147396018-147396018 18
6 COSM129137619 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.135G>A p.K45= 3:147403964-147403964 18
7 COSM129143394 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.1026G>C p.P342= 3:147391059-147391059 18
8 COSM129143406 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.432C>G p.A144= 3:147396258-147396258 18
9 COSM129140070 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.464T>G p.V155G 3:147396226-147396226 18
10 COSM129139322 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.719A>C p.K240T 3:147395971-147395971 18
11 COSM101397802 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305= 13:99982979-99982979 18
12 COSM85177007 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 2:43225208-43225208 18
13 COSM85176734 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 2:43225235-43225235 18
14 COSM149327447 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.7759C>T p.Q2587* 16:72794923-72794923 18
15 COSM149289399 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1646C>T p.S549F 16:72958500-72958500 18
16 COSM149269648 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.1138C>T p.P380S 16:72959008-72959008 18
17 COSM149314213 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.727G>A p.D243N 16:72959419-72959419 18
18 COSM149266494 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10999G>A p.D3667N 16:72787277-72787277 18
19 COSM149325349 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10577G>A p.G3526D 16:72787699-72787699 18
20 COSM149310946 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.2933C>T p.A978V 16:72950752-72950752 18
21 COSM149314206 ZFHX3 skin,NS,carcinoma,squamous cell carcinoma c.10688G>A p.R3563K 16:72787588-72787588 18
22 COSM90301886 ZBTB16 skin,NS,carcinoma,squamous cell carcinoma c.342G>A p.L114= 11:114063642-114063642 18
23 COSM90306524 ZBTB16 skin,NS,carcinoma,squamous cell carcinoma c.360G>A p.K120= 11:114063660-114063660 18
24 COSM90305004 ZBTB16 skin,NS,carcinoma,squamous cell carcinoma c.355C>T p.L119= 11:114063655-114063655 18
25 COSM90301496 ZBTB16 skin,NS,carcinoma,squamous cell carcinoma c.1968G>A p.E656= 11:114250501-114250501 18
26 COSM90301486 ZBTB16 skin,NS,carcinoma,squamous cell carcinoma c.1038G>T p.L346F 11:114064338-114064338 18
27 COSM86072167 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 22:49883990-49883990 18
28 COSM102043517 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 23:2490119-2490119 18
29 COSM152021819 YES1 skin,NS,carcinoma,squamous cell carcinoma c.1499C>T p.S500F 18:724557-724557 18
30 COSM152022082 YES1 skin,NS,carcinoma,squamous cell carcinoma c.373G>A p.E125K 18:748017-748017 18
31 COSM152022165 YES1 skin,NS,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 18
32 COSM143038487 YAP1 skin,NS,carcinoma,squamous cell carcinoma c.1112C>T p.S371F 11:102223689-102223689 18
33 COSM101977239 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 2:61488193-61488193 18
34 COSM86796191 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 3:14158444-14158444 18
35 COSM86796162 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 3:14148727-14148727 18
36 COSM86796169 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 3:14148728-14148728 18
37 COSM86796177 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 3:14147976-14147976 18
38 COSM86796183 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815= 3:14147977-14147977 18
39 COSM91365587 WT1 skin,NS,carcinoma,squamous cell carcinoma c.930C>A p.N310K 11:32417597-32417597 18
40 COSM91375774 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1168C>T p.P390S 11:32396338-32396338 18
41 COSM91368242 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1139G>A p.R380Q 11:32396367-32396367 18
42 COSM91381427 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1250-1G>T p.? 11:32392756-32392756 18
43 COSM91378684 WT1 skin,NS,carcinoma,squamous cell carcinoma c.1238G>A p.R413K 11:32396268-32396268 18
44 COSM133760680 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 14:67659823-67659823 18
45 COSM96871736 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.628G>A p.V210I 1:117153187-117153187 18
46 COSM96872019 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.236T>A p.L79* 1:117156783-117156783 18
47 COSM96872341 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.610G>A p.E204K 1:117153205-117153205 18
48 COSM96873614 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.134C>T p.A45V 1:117156885-117156885 18
49 COSM96872367 VTCN1 skin,NS,carcinoma,squamous cell carcinoma c.137G>A p.G46E 1:117156882-117156882 18
50 COSM88291561 VHL skin,NS,carcinoma,squamous cell carcinoma c.337C>T p.R113* 3:10142184-10142184 18
Sources

Expression for Skin Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.
Sources

Pathways for Skin Squamous Cell Carcinoma

About this section

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.88 TP53 STAT1 RAF1 RAC1 NET1 MAP2K7
2
TGF-Beta Pathway 63
Show member pathways
 13.53 TP53 STAT1 RAF1 RAC1 NET1 MAP2K7
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 TP53 STAT1 RAF1 IL10 IFNA1 HRAS
4
IL-2 Pathway 63
Show member pathways
 13.26 TP53 STAT1 RAF1 RAC1 MAP2K7 HRAS
5
Phospholipase-C Pathway 63
Show member pathways
 13.11 TP53 RAF1 RAC1 NET1 HRAS BRAF
6
PI3K-Akt signaling pathway 36
Show member pathways
 13.03 TP53 STAT1 RAF1 RAC1 IFNA1 HRAS
7
fMLP Pathway 63
Show member pathways
 12.99 TP53 RAF1 RAC1 NET1 MAP2K7 HRAS
8
TCR Signaling (Qiagen) 63
Show member pathways
 12.96 TP53 STAT1 RAF1 RAC1 MAP2K7 HRAS
9
Human cytomegalovirus infection 36
Show member pathways
 12.94 TP53 STAT1 RAF1 RAC1 MAP2K7 IFNA1
10
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 12.91 TP53 STAT1 RAF1 RAC1 MAP2K7 IL10
11
Endometrial cancer 36
Show member pathways
 12.9 TP53 STAT1 RAF1 RAC1 HRAS BRAF
12
MAPK-Erk Pathway 66
Show member pathways
 12.88 STAT1 RAF1 RAC1 HRAS BRAF
13
Beta-Adrenergic Signaling 63
Show member pathways
 12.84 RAF1 RAC1 MAP2K7 HRAS BRAF
14
Measles 36
Show member pathways
 12.83 TP53 STAT1 RAF1 RAC1 MAP2K7 IFNA1
15
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.82 STAT1 RAF1 RAC1 HRAS BRAF
16
Pathways in cancer 36
12.78 TP53 STAT1 RAF1 RAC1 IFNA1 HRAS
17
MAPK signaling pathway 1 36
12.77 TP53 RAF1 RAC1 MAP2K7 HRAS BRAF
18
Development HGF signaling pathway 22
Show member pathways
 12.73 TP53 RAF1 RAC1 MAP2K7 HRAS BRAF
19
Glioma 36
Show member pathways
 12.72 TP53 RAF1 MAP2K7 HRAS BRAF
20
Immune response NFAT in immune response 22
Show member pathways
 12.68 RAF1 RAC1 MAP2K7 IL10 HRAS
21
4-1BB Pathway 63
Show member pathways
 12.66 TP53 STAT1 RAF1 MAP2K7 HRAS BRAF
22
T cell receptor signaling pathway 36
Show member pathways
 12.64 STAT1 RAF1 MAP2K7 IL10 HRAS
23
Immune response IL-23 signaling pathway 22
Show member pathways
 12.62 TP53 STAT1 RAC1 IL10 HRAS
24
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.55 RAF1 RAC1 IFNA1 HRAS BRAF
25
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.53 TP53 RAF1 RAC1 HRAS BRAF
26
ErbB signaling pathway 1 36
Show member pathways
 12.47 TP53 STAT1 RAF1 RAC1 MAP2K7 HRAS
27
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.45 RAF1 RAC1 HRAS BRAF
28
Development FGFR signaling pathway 22
Show member pathways
 12.45 RAF1 RAC1 MAP2K7 HRAS
29
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.44 RAF1 RAC1 HRAS BRAF
30
Development IGF-1 receptor signaling 22
Show member pathways
 12.43 TP53 STAT1 RAF1 HRAS
31
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.42 RAF1 RAC1 NET1 MAP2K7 HRAS BRAF
32
CNTF Signaling 63
Show member pathways
 12.38 STAT1 RAF1 HRAS BRAF
33
Type I Interferon Signaling Pathways 64
Show member pathways
 12.34 STAT1 RAC1 NET1 IFNA1
34
Toll Comparative Pathway 63
Show member pathways
 12.34 TP53 STAT1 RAF1 RAC1 HRAS
35
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.33 STAT1 RAF1 IL10 IFNA1 HRAS
36
Proteoglycans in cancer 36
12.32 TP53 RAF1 RAC1 HRAS BRAF
37
VEGF Signaling Pathway 66 60
Show member pathways
 12.28 RAF1 RAC1 MAP2K7 HRAS
38
Tuberculosis 36
12.28 STAT1 RAF1 IL10 IFNA1
39
IL-1 Family Signaling Pathways 64
Show member pathways
 12.26 STAT1 RAF1 MAP2K7 HRAS
40
C-type lectin receptor signaling pathway 36
Show member pathways
 12.25 STAT1 RAF1 IL10 HRAS
41
mTOR Pathway 70
Show member pathways
 12.22 TP53 RAF1 HRAS BRAF
42
RANK Signaling in Osteoclasts 63
Show member pathways
 12.2 STAT1 RAF1 RAC1 MAP2K7 IL10 HRAS
43
Development ERBB-family signaling 22
Show member pathways
 12.2 TP53 STAT1 RAF1 RAC1 MAP2K7 HRAS
44
Integrated Breast Cancer Pathway 1
12.19 TP53 STAT1 RAC1 BRAF
45
EGF/EGFR Signaling Pathway 1
12.16 STAT1 RAF1 RAC1 HRAS BRAF
46
FoxO signaling pathway 36
Show member pathways
 12.12 RAF1 IL10 HRAS BRAF
47
NGF Pathway 63
Show member pathways
 12.12 TP53 RAF1 RAC1 HRAS BRAF
48
Development EGFR signaling via small GTPases 22
Show member pathways
 12.1 STAT1 RAF1 RAC1 MAP2K7 HRAS
49
MAPK Pathway 70
Show member pathways
 12.06 TP53 STAT1 RAF1 BRAF
50
G12-G13 in Cellular Signaling 63
12.05 RAF1 RAC1 MAP2K7 HRAS
Sources

GO Terms for Skin Squamous Cell Carcinoma

About this section

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 TP53 RAF1 KLF4 IL10 HRAS
2 regulation of cell proliferation GO:0042127 9.56 TP53 STAT1 KLF4 BRAF
3 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.4 KLF4 IL10
4 somatic stem cell population maintenance GO:0035019 9.33 RAF1 KLF4 BRAF
5 regulation of axon regeneration GO:0048679 9.32 KLF4 BRAF
6 positive regulation of protein phosphorylation GO:0001934 9.26 RARRES2 RAF1 RAC1 HRAS
7 positive regulation of transcription, DNA-templated GO:0045893 9.1 TRIM44 TP53 STAT1 MAP2K7 KLF4 IL10

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.35 TP53 STAT1 RAF1 RAC1 MAP2K7
2 transcription cofactor binding GO:0001221 9.16 TP53 KLF4
3 promoter-specific chromatin binding GO:1990841 8.8 TP53 STAT1 KLF4
Sources

Sources for Skin Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....